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Overview The Java class CGModcl models the human health effects of exposure to phosgene (CG) gas, including hmnan performance capability during and after exposure. CGModel's method ology for estimating performance decrement is well established [2, 3, 6, 12 14] and underlies the casualty estimates generated by modules such as IIDModel, GI3Model, VXModel, and ClModel. In this report. we describe this methodology and show how we implemented it in CGModel. Figure 1 illustrates the key values ca.lculaLed by CGModel. Given a CG vapor exposure, CGModcl estimates four time values related to the progression of injury: onset time, seek treatment time, litter time, and either time to return to duty (RTD) or time to death. Figure 2 illusLrates the two main steps in CGModcl's performance calculation. First, CGModel estimates the severity of the signs and symptoms of injury resulting from a phos gene C:>..xposure. This estimate, a time-dependent severity v<�ctor, represents a quaJltification of the physiological effects of the exposure. The four components of the severity vector, real numbers between 1 and 5, correspond to fom sign/symptom (S/S) categories and de scribe the severity of the effects associated with each category. In Section 1 we list the S/S categories used by CGModel, give descriptions of the severity values 1, 2, 3, 4, and 5 (for each S/S category ), and describe how CGModel associat<'. S severity vectors with phosgene exposur0.s. Second, CGModel maps cad1 severity vector to a performance value P, where 
Time Dependent Performance
Data from experiments.
--accident data. wartime
reports.
-
Input from S.MEs + regression analysis. Figure 2 : Overview of CGModel performance calculation.
Step <D utilizes dcita from labo ratory experiments, data from accidental relcas0, s of phosgene, and wartime reports.
Step ® utiliz:es SME (Subject Matter Expert)-provided performance decrement estimates and re gression. Lower right graph shows performance curves associated with increasingly severe exposures.
0 � P � 1. This task-specific mapping model::; the increase in task time due to phosgene exposure. In Section 2 we give the performance function P and plot performance curves (100 · P(t)) for several exposure scenarios. In Section 3 we show how CGModel us<: ' ,s P(t) to estimate time phased casualties. Finally, in Section 4 we describe how CGModel estimates time to RTD or time to death.
1

Signs and Symptoms
In this section we describe how CGModel associates a time dependent severity vector with a given phosgene exposure (i.e., Step <D in Figure 2 ). Before giving details about
Step <D, however; we must briefly discuss Step@. Two key steps in defining Step® are the following:
1. determine the performance decrements associated with a base set of severity vectors;
2. derive the performance model's regression coefficients (see Equation 2 ), so that perfor mance predictions can be made for arbitrary severity vectors.
In previous applications of this methodology, the fi rst task mentioned above was ac complished by interviewing SMEs or conducting performance assessment batteries. For this iitudy, however) time eonii traints necessitated an alternative approach. Therefore, we defined
Step@ by utilizing regression coefficients from a previous human response model [14] . given phosgene exposure and the elapsed time since the beginning of the exposure ( corre sponds to
Step (j) in Figure 2 ). model, which describes the effects of exposure to mustard (HD), utili?lcd the S/S categories and severity levels given in Table 1 . Therefore, CGModel also uses Table 1 to describe symp tom severity. In surmnary, the symptomatology associated with phosgene exposure (which can be regarded .a.. s a subset of the symptomatology associated with HD exposure) can be adequately de::;cribcd using Table 1 , so we used Table 1 and the regression coefficients from a previous study [14] as the ba.. <;is for Step ®. The S/S categories and severity level descriptions given in Table 1 therefore form the basis of mapping G), which is outlined in Figure 3 . 
4
Headache and fever, vomited several times and will again.
5
Pounding headache, dry heaves, fatigued from vomiting.
Respiratory Dan1agc
1
No effect.
2
Dry mouth , dry cough, snee-.
.dng, and runny nose.
3
Sore throat, continuous coughing, hoarse voice, chest feels Light.
4
Hurts to breathe, hacking cough, cannot speak. Figure 1) and applying an interpola tion/ extrapolation algorithin. We estimated the shape of the hmcffcct loci in Figure - t by considering exposure standards and guidelines (see Tables :2 and 3) . To associate physiolog ical effects with a given contour {i.e., to dev(�lop Table 7 , which describes time dependent sympLomatology), however, we considered data from rnulLiple sources in the literature.1
Effective Dosage Vector After calculating Dv, CGModel calculates effective dosages for each S/S category (see Table 4 )
. Note that CGModel docs not model liquid exposures and that CGModcl as�:mrnes protection is unavailable. CGModd uses the effective respiratory dosage DRE to calculate patient condition codes (see Table 6 ).
Physical exertion can signifi cantly intensify the effects of phosgene and cause phosgene's effcets to appear earlier [23, p.II 3), [26] . CGModcl describes this potentiation using the facLor F, which depends on Dv, the respiratory minute volume, and the level of physical activity (�cc Tables 4 and 5 ). Currently, CGModel uses regression coefficients for the 105 mrn arti llery loader {see Sec. 2), so the factor F is set to model heavy activity.1 The effective 1 We note that, because we h�ed our isoeffect calculations ou AECL and MEG values, it would be more accura.t.e to say that each contour represents exposures that. are "similarly disabling." Thus, our model assumes that "simil arly disabling" implies "similar symptomatology." This is not necessarily true, of course, and a more dct.aile<i model would be needed to describe certain characteristics of S/S severity due to phosgene exposure. For example, "exposures to 2 ppm for 80 minutes will not cause any irritation but result in pulmonary oedema some 12-16 hours later" [20. p.l50 ]. This exposure implies Dv = 516 mg·min/m3 (sec Table 2 :�). However, if Doc(= Dv) = 516, our model predicts eye irritation immediately after the exposure (see Table 7 ).
2If the task (upon which the performance calculation is based) can be changed (by users of th<l CGModel 
systemic dosage Dsy and the effective respiratory dosa,gc DHF: depend on F; therefore, F affects both performance and the probability of lethality (scr Eq. :�). In effect, F reduces the median lethal dosage (by 10% for light activity, 25% for heavy activity).
Effective Time Since Exposure The symptom severity vector also depends on the ef fe ctive time since exposure -r, where
class) in future versions of this software, the activity level upon which F is ba..<;e d could be made adjustable, too. mg · min/m 3 (potentiation is not modeled for D less than 100 mg·rnin/m3; see Table 26 ).
Light Activity Severity Vector and S/S Complex CGModcl calculates the severity vector (SsK, Ssy, SH.R, Soc) using Table 7 and an interpolation algorithm. Finally, ihe S/S complex x is defined by x = (1, SsK, Ssy, Snt:, S'oc).
The value of the first component of the S/S complex, 1, results from the regression analysis thai underlies the performance function in Equation 2.
Performance
Mapping @ in Fig. 2 was constructed using SME input and logistic regression, as described in section 8.3 of [ 11] . Specifically, CG.Nlod.el utilizes the following performance function to map S/S complexes :c to performance values P (0 � P � 1): 3 Onset Time, Seek Treatment Time, Litter Time,
Work Efficiency
CGModel uses P(t) to calculate onset time (ron.,et), seek treatment time (r. ,1�ek), and litter time ( rlitt1,r ). The onset time equals the amount of time that elapses beL ween the point at which Exposv. TeDuration = DosageDurat'ion/2 and the point at whlch P = 0.995. The seek treatment time and litter time arc calculated in a similar manner (see Table 8 and Figure G ). Litter (rlitter) 0.25 Table 9 : Calculation of work efficiency for the ca.<;e in which min {P} � 0. 75 .
Case vVork Efficiency
< Tonset 100
T<mset � T < Tseek 
Figure 6: �otional performance vs. effective time since exposure r and exposure duration.
where DRJ:: is the respiratory system effective dosage (see Table 4 ), PS is the probit slope, LCt50 is the median lethal dosage, and <I> is Lhe cumulative distribution function of the standard normal distribution (model parameters are given in Table 11 ). CGModel then determines the lethality of the exposure based on a random number Ran E [0, 1] that is passed to CGModel. If Ran:::; PL, the exposure is considered lethal and the time to death is set equal to 1.5 days (see Table 32 ). If Ran> PL, the exposure Lc;; nonlethal and CGModel calculates r1t rD·
Time to RTD If the exposure is nonlethal and rseek is defined (i.e., minimum perfor mance is less than or equal to 0.75), CGModeJ uses P(t) to calculate ru:rD, the time to RT D. If r * equals the time that elapses between the point at which Expo.cmreDuralion = DosageDuration/2 and the point at which P returns to 0.75 (see Fig. G 
TR:J'D = max{r * , Tscek + 24 hours}.
Time to RI'D is not defined if the minimum performance is greater than 0.75.
Assumptions and Limitations
• CGModcl rnodeb inhalation effects only4•5
4Phosgcue "doe1; uot cause lung effects when absorbed through the skin, injected, or orally ingested" [26] 5 "Inhalation is t.hc most important route of exposure for phosgene" [lb, p.l6]. 6 Appendix A: Table 7 The following methodology was used to develop Table 7 , which describes the severity vector's clepcnclence on effective dosage and effective time since exposure.
First, we performed a literature search to study the effects6 of phosgene exposure (our findings arc summari:l;ed in Sec. 7) . Using the data we gathered, we then defined four concentration bands that (roughly) correspond to four increasingly severe levels of exposure. Table 12 describes these bands and summarizes our rationale for choosing them. These concentration bands correspond to the dosage bands in Table 7 .
Next, for each S/8 category in Table 1 , we defined time-dependent severity values as sociated with the following four effective dosage values: G1 = J4 .1 · 81, G2 = J8 1 · 182, Table 7 and are used in the interpolation algorithm mentioned in Sec. 1). Graphs of these functions are given in Fig. 7 . We defined these severity functions based on data from our literature search (summarized by Tables 13 31) , the severity level definitions given in Table l , and the notion that, for any fixed time t, severity should be ar1 increasing function of dosage.
Finally, we combined the severity functions into the time dependent severity vectors shown in Table 7 . That is, Table 7 is ar1 alternate representation of the data shown in Fig. 7 (the dosage ranges in Table 7 actually refer to the discrete dosage values Gi that appear in Fig. 7 ).
Appendix B: Summary of Literature Search
Tables 13 31 summarize the data thai was used to construct the severity functions in Fig. 7 .
Our literature search focused on collecting four pieces of information about phosgene ex posures: the magnitude of the exposure (described in the tables below by concentration, exposure duration, dosage, and Dv7), the effects of the exposure (Effects/Comments), the time'{ at which the dfccts begin (Tbegin), and the time at which the cifcds end (Tend) · Usually 6 Skin damage, systemic damage, respiratory damage, and ocular damage (see Table 1 ).
7 Concentration, expo sure duration, and/or dosage were given by the literature; we calculated Dv using the algorithm described in Sec. 1. workweek" [1. '5] " C: "ceiling REL .. unless noted otherwise, the ceiling value should not be <lxceeded at any time" [15] d Exposure time betwflen I and 30 minutes (see Fig. 4 ).
e Exposure time betw1..>cn I and 50 minutes (sec Fig. 4 ).
I "A<;; a. safety margin. IDLII value:; a1·c ba:;cd on effects that might occur as a com;cqucuce of a 3(}-miuutc e xposure" (I 5] Y Expo<;; ure time between 1 and 150 minutes (see Fig. 4 ). 
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Res pir ato rY Da mage To provide an overview of phosgene toxicity, we provide the following two excerpts:
Human exposure in both the general population and occupational setting is primarily by inhalation. . . . The primary route of exposure is by inhalation, the gas penetrates into the tissues of the respiratory tract and so only minimal amounts of phosgene arc distributed in the body. The very short half-life (0.026 seconds) in aqueous solutions precludes a sig nificant retention of phosgene in the body . ... The hydrolytic products of phosgene, i.e., hydrochloric acid and carbon dioxide, arc disposed of by the body through normal phys iological processes. Phosgene exerts its toxicity through acylation of proteins, as well a.. <; through the production of hydrochloric acid. The amino, hydroxyl and sulfhydryl groups in the protein appear to be the target for acylation leading to marked inhibition of several en hymes related to energy metabolism and a breakdown of the blood:air barrier. In all species studied, the lung is the major target organ. . .. In all species the characteristic pathological feature is the delayed clinical manifestation of pulmonary ed ema, which is dose-dependent. Pathological changes in the terminal bronchiolf' �'> and alveoli at low concentrations arc typ ical of a pulmonary irritant, whereas at higher exposures pulmonary edema occurs, leading to interference with gas exchange and death. . . . Phosgene exposure can result in eye and skin irritation. ... The target organ in humans, as in experimental animals, is the lung. After exposure to phosgene levels between 120 and 1200 mg/cu m-min, three distinct clin ica.l clinicopathological phases have been reported. The initial phase consists of pajn in the eyes and throat and tightness in the chest, often with shortness of breath, wheezing, and coughing; hypotension, bradycardia and rarely sinus arrhythmia. . '> can occur. The second or latent phase, which is often asymptomatic, can last as long a..<> 24 hr depending upon the level and duration of exposure. In the third phase, pulmonary edema may develop, leading to death in so . me cases. Populations exposed to phosgene after industrial accidents have reported a wide variety of symptoms, including headache, nausea, cough, dyspnea, fatigue, pharyngeal pain, chest tightness and pain, intense pain in the eye and severe lacrimation. . . . In view of the lack of exposure data . . . the conclusions regarding the chronic effects of phosgene that can be drawn are limited. [11] (as cited in [28] )
15
Although there is a paucity of acute human data containing known exposure concentrations and times, reports of human phosgene poisonings present a relatively consistent set of clini cal effects aud :sequelae. After acute phosgene cxpo::;ure, brief (:::; 20 min) ocular and throat irritation, cough, nausea and vomiting, and dh:�iness are experienced, followed by a period ( $ 24 h) of apparent well-being. After this clinical latency phase, cough accompanied by ex pectoration, a sensaiion of pain or tightness of the chest, shortness of breath, and a choking sen:-;ation <m� experienced. Clinical findings may indude hemowncentralion, leukocytosi s, rales, and pulmonary edema. After recovery, rapid shallow breathing, shortness of breath on exertion, and a sense of decreased physkal fitness m�y persist for months. Pulmonary emphysema. may occur with repeated exposure to phosgene. Epidemiology studies have shown no increase in cancer in workers exposed to phosgene compared with controls. No in formation concerning reproductive and developmental toxicity or genotoxicity was available [18, "40-y-old male") "As the damage progresses, the dys pnea will become more severe, and soon a cough will develop. If the damage is severe, the casualty will starL coughing up a clear, foamy sputum, the plasma from his blood that has leaked into his alveoli." "hacking cough"; accidenL (vic tim: "40-y-old male") "During the subsequent 'edema phase', the patient experienced progressive respiratory distress, sometimes symptoms like cough ing ... returned)) "initial irritation of mucous mem -
brane surfaces of lhe eyes)) 120 -1200 "initial "pain in the eyes" 120 -1200 "initial "clinical signs and symptoms are generally lacking . . . the length of this phase varies inversely with the inhaled dose" "At dosages exceeding 30 ppm ·min, the initial irritation and respiratory symptoms are followed by a second (possibly asymp�omatic) phase, the duration of which is inversely pro portional to the inhaled dose . ... af ter small doses, 24 -48 hours" "At dosages exceeding 30 ppm·min, the initial irritation and respiratory symp�oms arc fo llowed by a second (possibly asymptomatic) phase, the duration of which is inversely pro portional to the inhaled dose. After large closes, it may be 1 -4 homs" 
Skin Irritation
Pulmonary Edema
Cone ( :::; 5 days Effects/Comments "Initially, this may be mild, and the eventual severity of the shortness of breath (dyspnea) will depend on the amount of exposme. As the damage progresses, the dyspnea will become more severe, and soon a cough will develop." "[casualty) will find it increas ingly difficult to breathe, even at rest" "(casualty) . . . may progress to have dyspnea while at rest" "difficulty breathing" accident (victim: "23-y-old man (healthy nonsmoker)") "mild dyspnea" ; accident (victim: "40-y-olcl male") Efl:' ccls /Comment� SWI:'-l'E ("pulmonary architecture in swine is very similar to that of adult humans" ): "swine show a marked decrease in pH, P02, 02 satmation, dynamic compliance, and increased lung wet weight" "Recovery normally was achieved within 1 to 3 weeks" (pulmonary edema, respiratory insufficiency, etc.) "Documented cru;es show return to normal limits of lung function within a period of weeks, however complete recovery may take a pe riod of years" ''rnay cause no signs or symptoms initially, or symptoms may be due only to mild irritation of the air ways" Dosage Duration A measure of the effective duration of an exposure (this value is cal culated elsewhere and passed to CGModel).
Effective Time Since Exposure ( r) Time elapsed since ExposureDuralion = DosageDw·ation/2, that is, the time that has elapsed since the effective mid-point of the exposure. It is an analog of postexposure time for exposures of negligible duration.
Exposure Duration Time elapsed since the beginning of an exposure. This quantity, defined elsewhere and passed to CGModel, continues to increase even after the cessation of exposure. It should not be confused with dosage duration, which does not increase after the cessation of exposure.
Litter Time ( rl itter ) First effective time since exposure at which P = 0.25. The exposed person is presumed to require assistance to reach medical care after this time.
MEG Military Exposure Guideline
Onset Time ( To nset ) . First effective time since exposure at which P = 0.995. Indicates the time of first occurrence of signs or symptoms of injury.
PPM Parts per million (e.g., of phosgene gas) in air by volume.
RTD Return to Duty.
Seek Treatment Time ( rsee k ) First effective time since exposure at whi<.:h P = 0. 75. The · time at which an individual seeks treatment for his or her symptoms. SME Subject Matter Expert.
S /S Sign/Symptom.
Time to Death Equal to 1.5 days if, and only if, the exposure is lethal.
Time to RTD ( rm·v ) If the exposure is nonlethal, the minimum performance is less than or equal to 0.75, and r* equals the time that elapse..<; between the point at which E:r;posttreDur-ation = DosageDu,ralion/2 and the point at which P returns to 0.75, r nrn = max{ r * , -r:.eek + 24 hours}. This RTD time is different than that used in AMedP-8, where it was assumed that no treatment was avc1ilablc. In the context of the software that uses CGModel, the lower bound (rseek + 24 hours) on rm·o models time in the medical care system. Time to RTD is not defined if the minimum performance is greater than 0. 75.
